Journey Medical's Emrosi Now Covered For 65% Of U.S. Commercial Lives, Up From 29% In May

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025

Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase

SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that 65% of the 187 million commercial lives in the United States now have pharmacy benefit coverage for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release), the Company's recently launched treatment for the inflammatory lesions of rosacea in adults. This compares to 29% of commercial lives in May 2025. Journey Medical continues to execute on the launch of Emrosi, with expanded payer coverage anticipated to facilitate further growth in total prescription (TRx) demand.